Lars Fruergaard Jørgensen (born 29 November 1966)[1] is a Danish businessman, the Chief Executive of Novo Nordisk since January 2017 and Chairman of the European Federation of Pharmaceutical Industries and Associations.

[4] Jørgensen is President of the European Federation of Pharmaceutical Industries and Associations[2] and member of the Board of Directors at Danmarks Nationalbank.

[4] He has also served as a member of several company boards of directors, including Innate Pharma in France, Harno Invest, NNIT, and NNE Pharmaplan.

[5] On September 24, 2024, Jørgensen appeared before the Senate Committee on Health Education, Labor, and Pensions to defend Ozempic and Wegovy drug pricing.

[6] The committee, led by Bernie Sanders, reiterated the point that drug prices should be substantially lowered.